Search clinical trials for: Betrixaban

Total 12 results

Portola Pharmaceuticals

Completed

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

Health Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin (EXPLORE-Xa)

Atrial Fibrillation

United States, Canada
Portola Pharmaceuticals

Completed

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter
Portola Pharmaceuticals

Terminated

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

Bleeding

United States
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)

Terminated

Study Evaluating Betrixaban in Pediatric Participants

VTE Prophylaxis

United States, United Kingdom, Russian Federation, Ukraine
Portola Pharmaceuticals

Completed

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Healthy
Portola Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

Germany
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Portola Pharmaceuticals

Completed

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Healthy Subjects
Brian O'Neill MD
Lifetech Scientific (Shenzhen) Co., Ltd.

Not yet recruiting

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (CORRAL-AF)

Atrial Fibrillation | Left Atrial Appendage Thrombosis | CVA

United States
Portola Pharmaceuticals

Completed

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) (APEX)

Venous Thromboembolism (VTE)

Belgium, Israel, Italy, United States, France, Bulgaria, Australia, Germany, Russian Federation, Hungary, Singapore, Austria, Chile, Canada, United Kingdom, Czechia, Poland, Spain, Romania, Latvia, South Africa, Croatia, Serbia, Peru, U... and more
Portola Pharmaceuticals

Completed

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Thromboembolism

Canada

Search clinical trials for: Betrixaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations